Development asset linked to ZhongShan Hospital, Fudan in public FDA and regional records.
pharma · Interstitial Lung Disease (ILD) · Gastrointestinal Disease
ZhongShan Hospital, Fudan
Shanghai Zhongshan Hospital
ZhongShan Hospital, Fudan drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
1936 Founded
624 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1936
- Employees
- 624
- Programs
- 3
- Drugs
- 8
- Patents
- 0
ZhongShan Hospital, Fudan pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ZhongShan Hospital, Fudan drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to ZhongShan Hospital, Fudan in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in ZhongShan Hospital, Fudan's portfolio.
-
Development asset linked to ZhongShan Hospital, Fudan in public FDA and regional records.
-
Development asset linked to ZhongShan Hospital, Fudan in public FDA and regional records. Mechanism: Adrenergic receptor agonist.
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to ZhongShan Hospital, Fudan in public FDA and regional records.
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor